



World Leader in Innovation

Richard Penny, Senior Fund Manager
Legal & General Investment Management

Market summary

A year in review and outlook for 2017


Small Cap market

- UK equities fair value
- Low growth, low inflation world
- GBP Sterling looks undervalued / M&A on the horizon
- Sub £200m stressed


State of Technology

- World leading universities / IP
- Technology trends remain on track
- Good technology can take time to reach investable stage
- AIM / Tax / Brexit

Shrinking supply of patient equity capital:




Turning innovation into profitable stock picking




Discovered in 1928... but was not adopted as an antibiotic until the 1940's




Product relevance and adoption



Business model



Right price!



Biotech

Clinical stage drug discovery (phase III late stage) and development companies:

- **ImmuPharma**
- **Diurnal**
- **Midatech**
- **Motif**
- **Faron Pharmaceuticals**

Immunotherapy

Distinct area driven by genetics


- **Faron Pharmaceuticals**
- **Maxcyte**
- **Scancell Holdings**
- **RedX**

Medtech / Medical Devices


Manufacturer of minimally invasive products (endoscopes etc):

- **Creo Medical**
- **Collagen Solutions**
- **Omega Diagnostics**


65% of marketed pharma NMEs were originated by small-mid size BioPharma



Global licensing of R&D stage assets



Key themes from Consumer Electronics Show (CES) 2017



Investable UK Tech Opportunities

